The latest news, announcements and press releases from ibet.
ViSync® aims to develop innovative solutions to address the unmet technical needs of pharmaceutical companies in the cell and gene therapy sector. The venture will leverage Hovione’s extensive expertise in pharmaceutical development, particle engineering and industrialization, with iBET’s cutting-edge research in biotechnological sciences.
One of the first focus areas of ViSync® will be to develop technologies that improve delivery and stabilization of new modality therapies.
The launch ceremony was attended by representatives from both iBET and Hovione, who played an important role in the establishment of the company.
The event took place at the iBET Biofarma Building in Oeiras, where ViSync will also be headquartered.
This is the News section of the company profile page for ibet on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
